Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Clin Breast Cancer. 2018 Mar 15;18(5):387–394. doi: 10.1016/j.clbc.2018.03.010

Figure 2. Best Response of Target Lesions in Evaluable Patients (n=35).

Figure 2.

P= prior therapy with paclitaxel

Green: patients with triple negative breast cancer

Blue: patients with ER positive disease

*Best Response = Progression of Disease (due to development of new lesions or progression of non-measurable disease)